cortactin binding protein 2Genealiases: C7orf8 · CORTBP2 · Orf4
Q-omics provides the consensus-scored CTTNBP2 profile across patient tissues and cancer cell-line models. CTTNBP2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CTTNBP2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CTTNBP2 protein abundance shows 19,929 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where CTTNBP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTTNBP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTTNBP2 survival associations across molecular data types. CTTNBP2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (11) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTTNBP2 RNA expression–survival associations across cancer types. High CTTNBP2 expression shows unfavorable associations in BLCA, but favorable associations in KIRC, LUSC, MESO, BRCA and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CTTNBP2 RNA expression.
This table summarizes CTTNBP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CTTNBP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTTNBP2 shows lower tumor expression in HNSC, THCA, UCEC, BRCA and BLCA and higher tumor expression in COAD. The HNSC box plot shows higher CTTNBP2 RNA expression in normal versus tumor tissue (log2 FC = −1.329, t-test p < 0.001).
This table shows molecular features associated with CTTNBP2 in patient tissues and cancer cell lines. In patient samples, CTTNBP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CTTNBP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
